Work

Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in nonpancreatic neuroendocrine tumors (NET).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.e15004

Authors: Monica M. Mita, Edward M. Wolin, Tim Meyer, John J. Nemunaitis, Emily K. Bergsland, Amit Mahipal, Lilly Wong, Xiaoling Wu, James Carmichael, Rajesh Chopra, Kristen Hege, Johanna C. Bendell

Institutions: Cedars-Sinai Medical Center, University College London, Mary Crowley Cancer Research Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Moffitt Cancer Center, Celgene (United States), Tennessee Oncology

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2751835296

Cites:

Cited by: 5

Related to: 10